

1 **NOTE: This is the pre-peer reviewed version of the following article: Local arginase**
2 **inhibition and low-dose sodium nitroprusside administration do not modulate heat loss**
3 **responses in young and older men during exercise. Meade RD, Fujii N, McGarr GW,**
4 **Alexander LM, Boulay P, Sigal RJ, Kenny GP. J Appl Physiol (1985). 2019 Apr**
5 **1;126(4):1129-1137. doi: 10.1152/jappphysiol.00657.2018. Epub 2019 Jan 17. which has**
6 **been published in final form at**
7 **<https://www.physiology.org/doi/abs/10.1152/jappphysiol.00657.2018>**
8

9 **Local arginase inhibition and low-dose sodium nitroprusside administration do**
10 **not modulate heat loss responses in young and older men during exercise.**

11
12 Robert D. Meade¹, Naoto Fujii^{1,2}, Gregory W. McGarr¹, Lacy M. Alexander³,
13 Pierre Boulay⁴, Ronald J. Sigal^{1,5,6}, Glen P. Kenny^{1,6}

14
15 ¹Human and Environmental Physiology Research Unit, School of Human Kinetics,
16 University of Ottawa, Ottawa, Ontario, Canada, ²Faculty of Health and Sport Sciences,
17 University of Tsukuba, Tsukuba City, Japan; ³Department of Kinesiology, Noll
18 Laboratory, Pennsylvania State University, University Park, Pennsylvania, USA;
19 ⁴Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, Canada;
20 ⁵Departments of Medicine, Cardiac Sciences and Community Health Sciences,
21 Faculties of Medicine and Kinesiology, University of Calgary, Calgary, Alberta, Canada,
22 and ⁶Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
23 Ontario, Canada.

24
25
26 **Running head:** Arginase, nitric oxide and heat loss, exercise, passive heating
27
28

29 **Author Contributions:**

30 R.D.M., N.F. L.M.A. and G.P.K. conceived and designed experiments. R.D.M., N.F.,
31 and G.W.M. contributed to data collection and analysis. All authors interpreted the
32 experimental results. R.D.M. drafted the manuscript. All authors edited and revised the
33 manuscript. All authors approved the final version of the manuscript. Experiments took
34 place at the Human and Environmental Physiology Research Unit located at the
35 University of Ottawa.

36
37 Dr. Glen P. Kenny
38 University of Ottawa,
39 School of Human Kinetics,
40 125 University Private, Room 367
41 Montpetit Hall
42 Ottawa, Ontario, Canada
43 K1N 6N5
44 (613) 562-5800 ext. 4282
45 (613) 562-5149 (fax)
46 Email: gkenny@uottawa.ca

47 **ABSTRACT**

48 Age-related impairments in cutaneous vasodilation and sweating may result from
49 increased arginase activity (which can attenuate endogenous NO production), and/or
50 altered NO sensitivity of the thermoregulatory end-organs (i.e., cutaneous vasculature
51 and sweat gland). We evaluated whether local arginase inhibition or low-dose sodium
52 nitroprusside (SNP; NO donor) modulate cutaneous vascular conductance (CVC) and
53 sweat rate (SR) in young (n=9, 23±3 years) and older (n=9, 66±6 years) men during an
54 exercise-heat stress. We also assessed the influence of these treatments during whole-
55 body passive heating in older men (n=7, 64±7 years). During two 30-min bouts of
56 moderate-intensity cycling (Ex1 and Ex2) in the heat (35°C), CVC and SR were
57 measured at forearm skin sites perfused with: 1) lactated Ringer's (Control); 2) 5mM
58 N^ω-hydroxy-nor-Arginine + 5mM S-(2-boronoethyl)-L-cysteine (Nor-NOHA+BEC,
59 arginase-inhibited); or 3) 1μM SNP. The influence of these treatments on CVC and SR
60 was also evaluated at passively-induced elevations in esophageal temperature (ΔT_{es})
61 equal to those in Ex1 (0.6°C) and Ex2 (0.8°C). In both age-groups, CVC and SR were
62 similar to Control at Nor-NOHA+BEC and SNP during exercise (all $P \geq 0.10$). During
63 passive heating however, CVC was augmented compared to Control by Nor-
64 NOHA+BEC at ΔT_{es} of 0.6°C (23±8% CVC_{max} ; $P=0.04$) and 0.8°C (20±7% CVC_{max} ;
65 $P=0.04$). By contrast, no effect of SNP on CVC was seen (both $P \geq 0.66$) and SR was not
66 influenced by any treatment during passive heating ($P=0.89$). Thus, neither arginase
67 inhibition nor low-dose SNP modulate CVC or SR during moderate exercise in the heat,
68 but arginase attenuates CVC in older men during whole-body passive heat stress.

69 **Key words:** Aging, nitric oxide, heat stress, skin blood flow, sweating

70 NEW AND NOTEWORTHY

71 In the current study we demonstrate that neither local arginase inhibition nor low-
72 dose sodium nitroprusside administration influence the forearm cutaneous vasodilatory
73 and sweating responses in young or older men during an exercise-heat stress.
74 Consistent with previous findings, however, we observed augmented cutaneous blood
75 flow with arginase inhibition during whole-body passive heat stress. Thus, arginase
76 differentially affects cutaneous vasodilation depending on the mode of heat stress but
77 does not influence sweating during exercise or passive heating.

78

79

80 INTRODUCTION

81 Aging is associated with a decline in cutaneous vasodilatory (17-20, 23, 44, 45)
82 and sweating (21, 22, 27-30, 44) responses to both exercise- and passively-induced
83 heat stress, with attenuated whole-body heat dissipation during exercise evident in
84 adults as young as 40 years of age (27). Contributing to these age-related impairments
85 are alterations in factors affecting heat loss at the level of the end-organ (i.e., cutaneous
86 vasculature and eccrine sweat gland). For instance, nitric oxide (NO) is required for full
87 expression of cutaneous vasodilation and sweating during heat stress (exercise or
88 passive heating) in the young (8, 9, 17-20, 34-38, 45, 49). In older adults however, its
89 contribution to these heat loss responses is diminished (9, 11, 17-20, 28, 30, 45, 46).

90 Potentially underpinning the attenuated NO-dependent cutaneous vasodilation
91 and sweating responses in older adults is elevated arginase activity in the skin. In
92 comparison to NO synthase, arginase preferentially binds L-arginine, the common
93 precursor for both enzymes. Thus, an age-related increase in arginase activity may
94 reciprocally inhibit endogenous NO production due to substrate depletion (4, 50). During
95 whole-body passive heating in older adults, local arginase inhibition has been shown to
96 augment cutaneous vasodilation to a level comparable to their younger counterparts
97 (19, 20, 45). Additionally, studies of eccrine sweat urea nitrogen (a primary end-product
98 of arginase) suggest that arginase is also localized in the sweat gland (15) and
99 increased urea in the sweat of older vs. younger adults (2) indicates up-regulated sweat
100 gland arginase activity with aging. That said, the role of arginase in mediating
101 cutaneous vasodilation and sweating during exercise has not been directly evaluated,

102 and it is known that end-organ modulators of heat loss during whole-body passive
103 heating are not always consistent with those during exercise (8, 33).

104 In addition to up-regulated arginase activity, changes in the sensitivity of the
105 thermoregulatory end-organs to NO may play a role in the age-related reductions in NO-
106 dependent heat loss. In response to a NO donor, attenuated cutaneous vasodilation has
107 been observed in older relative to younger adults (18); however, others have found no
108 age-related differences in cutaneous vasodilation during exogenous NO administration
109 (10). Regardless, it is unknown whether the sensitivity of the cutaneous vasculature and
110 eccrine sweat gland to NO is altered in older adults during exercise.

111 Restoring endogenous NO synthesis through arginase inhibition or providing
112 exogenous NO might alter thermoregulatory responses during exercise heat stress in
113 older adults. Therefore, the purpose of this study was to assess the independent
114 influences of local arginase inhibition and exogenous NO administration on cutaneous
115 vasodilation and sweating in older men during exercise in the heat (35°C). It was
116 hypothesized that local arginase inhibition to improve endogenous NO production via
117 NO-synthase or exogenous NO administration through low-dose sodium nitroprusside
118 (SNP; a NO donor) would augment cutaneous vasodilation and sweating in older but
119 not younger men. Furthermore, given that it has been repeatedly demonstrated that the
120 mechanisms regulating these heat loss responses can differ between exercise- and
121 passively-induced heat stress, we also evaluated the influence of arginase inhibition
122 and low-dose sodium nitroprusside administration on cutaneous vasodilation and
123 sweating in older men during whole-body passive hyperthermia.

124

125 **MATERIALS AND METHODS**

126 **Ethical approval**

127 This study was in accordance with the *Declaration of Helsinki* and was approved
128 by the University of Ottawa Health Sciences and Science Research Ethics Board. Prior
129 to their participation in the study, informed consent was obtained from all volunteers.

130

131 **Participants**

132 A total of nine young and sixteen older men participated in the study (see results
133 section for physical characteristics). Of these individuals, all of the young and nine of
134 the older men completed an exercise-heat stress test and the remaining seven older
135 men participated in the whole-body passive heating protocol. All participants were
136 healthy (i.e., no history of cardiovascular, metabolic or respiratory disease and not
137 currently taking medication related to these conditions) and habitually active (i.e.,
138 performing ≥ 30 -min of structured physical activity a minimum of 2 times per week) as
139 determined by a standardized questionnaire (26). Men were chosen given the potential
140 modulation in the mechanisms underpinning heat loss associated with fluctuations in
141 female sex hormone levels (i.e., estrogen and progesterone) (5, 6). Furthermore,
142 women exhibit an altered capacity to dissipate heat (for a given level of heat stress)
143 independent of sex-related differences in body morphology and aerobic capacity in
144 comparison to males (12-14).

145

146 **Experimental Design**

147 Each participant completed one preliminary and one experimental session
148 (exercise- or passively-induced heat stress). Prior to the start of each session,
149 participants were instructed to refrain from alcohol, caffeine and/or strenuous physical
150 activity for a minimum of 24 hours. Furthermore, participants were instructed to drink
151 500 mL of water the night before as well as ~2 hours prior to each session to ensure
152 adequate hydration. During the preliminary session, body height, mass and density
153 were measured. For those participating in the exercise-heat stress protocol, peak rate of
154 oxygen uptake ($VO_{2\text{peak}}$) was also determined. Body height and mass were measured
155 with a stadiometer (Detecto, model 2391, Webb City, MO, USA), and a digital high-
156 performance weighing terminal (model CBU150X, Mettler Toledo Inc., Mississauga, ON,
157 CAN), respectively. Body surface area was calculated from the measurements of body
158 height and mass (7). Body density was measured using the hydrostatic weighing
159 technique and used to calculate body fat % (43). $VO_{2\text{peak}}$ was assessed using an
160 automated indirect calorimetry system (MCD Medgraphics Ultima Series; MGC
161 Diagnostics, MN, USA) during a progressive incremental cycling protocol on a semi-
162 recumbent cycle ergometer (Corival, Lode B.V., Groningen, the Netherlands). The
163 protocol began with 1 min of cycling at a starting workload of 100 W for the younger
164 adults and 60 W for the older adults. Following the first minute, the workload was
165 increased by $20 \text{ W}\cdot\text{min}^{-1}$ until volitional fatigue and/or the participant could no longer
166 maintain a pedaling cadence $>50 \text{ revolutions}\cdot\text{min}^{-1}$.

167 As mentioned above, the experimental session consisted of either an exercise-
168 induced heat stress or whole-body heating at rest. In both protocols participants

169 provided a urine sample for the measurement of urine specific gravity (Reichert TS 400
170 total solids refractometer, Reichert Inc., Depew, NY, USA) upon arrival to the laboratory,
171 prior to a baseline measurement of body mass. Thereafter, four microdialysis fibers
172 (Bioanalytical Systems Inc., West Lafayette, IN, USA) were inserted in the dermal layer
173 of the dorsal forearm skin while participants rested in an upright-seated position in a
174 thermoneutral ($\sim 24^{\circ}\text{C}$) experimental room. Fibers were inserted under aseptic
175 conditions by advancing a 25-gauge needle 20-25 mm. The needle was withdrawn after
176 the fiber passed through the lumen, leaving a 10 mm dialysis membrane within the
177 dermal layer. Each fiber was secured to the skin using surgical tape and separated by
178 $\sim 2\text{-}4$ cm. All fibers were then perfused with lactated Ringer's solution for ~ 30 min at a
179 rate of $4\ \mu\text{L}\cdot\text{min}^{-1}$ via a micro-perfusion pump (model 400, CMA, Microdialysis, Solna,
180 Sweden). Each skin site was instrumented for the measurement of local cutaneous
181 blood flow and sweat rate.

182

183 *Exercise-heat stress*

184 In the exercise-heat stress protocol, participants entered a thermally controlled
185 chamber regulated to 35°C and 20% relative humidity following microdialysis fiber
186 insertion. For ~ 60 min, participants were seated on a semi-recumbent cycle ergometer
187 while the four microdialysis fibers were perfused at a rate of $4\ \mu\text{L}\cdot\text{min}^{-1}$ via a
188 microinfusion pump (Model 400, CMA Microdialysis, Solna, Sweden) with either 1)
189 lactated Ringer's (Control), 2) 10 mM N^{G} -nitro-L-arginine methyl ester (Sigma-Aldrich, St
190 Louis, MO, USA), to inhibit NO synthase activity (L-NAME), 3) 5 mM N^{ω} -hydroxy-nor-
191 Arginine (Nor-NOHA; Sigma-Aldrich) + 5 mM S-(2-boronoethyl)-L-cysteine (BEC;

192 Sigma-Aldrich) arginase inhibitors, to enhance endogenous NO synthesis (Nor-NOHA +
193 BEC), or 4) 1 μ M SNP (Sigma-Aldrich), an exogenous NO donor (low-dose SNP). The
194 concentration of each drug was based on previous work (8, 9, 11, 17-20, 37, 38, 46).

195 Following the ~60 min perfusion period, 10 min of baseline data collection
196 ensued followed by two successive 30 min bouts of semi-recumbent cycling at a
197 metabolic heat production of 400 W. Exercise was performed at a fixed rate of heat
198 production to ensure similar drives for whole-body heat loss between groups (24, 39).
199 Each exercise bout was followed by 20 min of recovery. An intermittent exercise
200 protocol was employed given the potential influence of intermittent exercise bouts on
201 the mechanisms underpinning the heat loss responses. Specifically, recovery from
202 exercise is associated with an attenuation of cutaneous vasodilation and sweating to
203 near baseline levels, followed by a rapid increase in these responses upon initiation of a
204 subsequent exercise bout (19). Following the second recovery, each microdialysis fiber
205 was perfused with 50 mM SNP at a rate of 6 μ L \cdot min⁻¹ to evaluate maximum cutaneous
206 blood flow. A measurement of blood pressure was taken once a stable plateau in
207 cutaneous blood flow was achieved (~20-30 min) for the determination of maximal
208 cutaneous vascular conductance (CVC_{max}). The remaining instrumentation was then
209 removed and a final nude body mass was obtained.

210

211 *Passive heating protocol*

212 Following completion of the exercise-heat stress study, a whole-body passive
213 heating sub-study was performed for the purpose of comparing the effects of arginase
214 inhibition and low-dose SNP administration on heat loss responses between active

215 (exercise) and passively-induced heat stress. Importantly, this protocol also allowed us
216 to compare our findings to previous work, in which augmentation of CVC in response to
217 arginase inhibition was observed in older adults during whole-body passive heating (19,
218 20). In this protocol, participants remained in the thermoneutral room ($\sim 24^{\circ}\text{C}$) in the
219 semi-recumbent position following fiber insertion while wearing a tube-lined water-
220 perfusion suit. The microdialysis fibers were perfused for ~ 60 min with the same agents
221 as in the exercise-heat stress protocol (i.e., Ringer, L-NAME, Nor-NOHA+BEC and low-
222 dose SNP), while suit temperature was maintained at 34°C . The temperature of water
223 perfusing the suit was then increased to 49.5°C to initiate whole-body heating. Once
224 esophageal temperature had increased by 0.8°C (similar to the peak increase in
225 esophageal temperature during exercise-heat stress), the suit water temperature was
226 reduced to 40°C and CVC_{max} was determined as described in the preceding section.

227

228 **Measurements**

229 Esophageal temperature was measured in both protocols with a pediatric
230 thermocouple probe ~ 2 mm in diameter (Mon-a-therm, Mallinckrodt Medical, St. Louis,
231 MO) inserted through the nose and advanced 40 cm. In one older participant (exercise-
232 heat stress), tympanic temperature was taken due to intolerance of the esophageal
233 probe. Mean skin temperature was calculated using 4 skin sites weighted to the regional
234 proportions: 30% chest, 30% bicep, 20% quad and 20% calf (42), measured during the
235 exercise protocol. Due to technical difficulties, mean skin temperature was not reported
236 for one young participant. Temperature data were collected with a data acquisition

237 module at a 15 s sampling rate and displayed and recorded with LabVIEW software
238 (version 7.0; National Instruments, TX, USA).

239 During both exercise-heat stress and whole-body passive heating systolic and
240 diastolic pressures were measured by manual auscultation every 5 min using a
241 validated mercury column sphygmomanometer (Baumanometer Standby Model, WA
242 Baum Co, Copiague, NY, USA). Mean arterial pressure was calculated as diastolic
243 pressure plus one-third the difference between systolic and diastolic pressure (i.e.,
244 pulse pressure). Additionally, heart rate data were recorded and stored every 5 s during
245 exercise using a Polar coded WearLink and transmitter, Polar RS400 interface, and
246 Polar Trainer 5 software (Polar Electro, Oy, Kempele, Finland).

247 Cutaneous red blood cell flux, an index of cutaneous blood flow expressed in
248 perfusion units, was locally measured at a sampling rate of 32 Hz via laser-Doppler
249 flowmetry (PeriFlux system 5000, Perimed, Stockholm, Sweden) using integrated laser-
250 Doppler flowmetry probes with a 7-laser array (Model 413, Perimed). Each probe was
251 placed over the center of each microdialysis fiber and housed within a specialized
252 ventilated sweat capsule (see below). Cutaneous vascular conductance (CVC) was
253 calculated as cutaneous red blood cell flux divided by mean arterial pressure (perfusion
254 units·mm Hg⁻¹) and presented as a percentage of CVC_{max}.

255 Specialized ventilated capsules, designed to cover the entire area of skin
256 perfused by the microdialysis fiber (40), were used for the measurement of local sweat
257 rate. Each capsule was placed directly over the center of each fiber membrane and
258 affixed to the skin using double-sided adhesive and topical skin glue (Collodion HV,
259 Mavidon Medical products, Lake Worth, FL, USA). Dry compressed air was passed

260 through each capsule at a constant flow rate ($0.4 \text{ L}\cdot\text{min}^{-1}$) while capacitance hygrometry
261 (Model HMT333, Vaisala, Helsinki, Finland) was used to measure the water content of
262 the effluent air. Connections between the gas tanks and sweat capsules, and between
263 the sweat capsules and hygrometers, comprised long vinyl tubes to allow for gas
264 temperature to equilibrate with ambient temperature. Local sweat rate was calculated
265 every 5 s using the water content of the effluent air times the flow rate and normalized
266 to capsule surface area ($\text{mg}\cdot\text{min}^{-1}\cdot\text{cm}^{-2}$).

267 During exercise, endogenous heat production was then estimated as metabolic
268 rate minus external work (24). The oxygen and carbon dioxide concentrations of expired
269 air were analyzed using electrochemical gas analyzers (AMETEK model S-3A/1 and
270 CD3A, Applied electrochemistry, Pittsburg, PA, USA), which were calibrated using a
271 gas mixture of known concentrations. A 3 L syringe was used to calibrate the turbine
272 ventilometer. Participants wore a full-face mask (Model 7600 V2, Hans-Rudolf, Kansas
273 City, MO, USA) attached to a 2-way T-shape non-rebreathing valve (Model 2700, Hans-
274 Rudolf). Oxygen uptake and respiratory exchange ratio were obtained as 30 s averages
275 and subsequently used to calculate metabolic rate (41).

276 Urine specific gravity (an index of body fluid status) was evaluated using a
277 handheld total solids refractometer (Model TS400, Reichter Inc., Depew, NY, USA) prior
278 to each experimental protocol. Participants with a urine specific gravity of <1.020 were
279 deemed adequately hydrated to begin the experimental session (3).

280

281 **Data analysis**

282 For the exercise-heat stress protocol, local forearm CVC and sweat rate at each
283 treatment site as well as esophageal and skin temperatures (both absolute values and
284 elevations from baseline) and heart rate were presented as 5-min averages of data
285 recorded at the end of each of the following time periods: baseline, exercise 1 (25-30
286 min), recovery 1 (15-20 min), exercise 2 (25-30 min) and recovery 2 (15-20 min). Blood
287 pressure data were presented as an average of the two measurements taken over 10
288 min at the end of each time period. CVC_{max} was determined from averaged CVC data
289 over a minimum of 2 min once a plateau was attained during the maximal cutaneous
290 vasodilation procedure at the end of the protocol. In the passive heating protocol,
291 average CVC and sweat rate data were determined over the time-interval
292 corresponding to increases in esophageal temperature of 0.6°C (0.55-0.64°C) and
293 0.8°C (0.75-0.84°C) (similar to the increase in esophageal temperature noted in the
294 older adults during exercise 1 and 2 of the exercise-heat protocol, respectively).

295

296 **Statistical Analysis**

297 Local CVC and sweat rate were analyzed for the exercise-heat stress protocol
298 using a two-way repeated-measures analysis of variance (ANOVA) for both the young
299 and older men with the factors of time period (five levels: baseline, exercise 1, recovery
300 1, exercise 2 and recovery 2) and of treatment site (four levels: Control, L-NAME, Nor-
301 NOHA + BEC and low-dose SNP). A separate two-way mixed model ANOVA was
302 performed with the factors of time (five levels) and age (two levels: young and older) to
303 compare physiological responses between age-groups – namely, the heat loss

304 responses at the Control site (i.e., CVC and sweat rate) as well as body temperatures
305 (i.e., esophageal and mean skin) and cardiovascular (i.e., mean arterial pressure and
306 heart rate) variables. A two-way mixed-model ANOVA with the factors of treatment site
307 (four levels) and age (two levels) was also used to evaluate local forearm CVC_{max}
308 (expressed in perfusion units \cdot mm Hg $^{-1}$) obtained during the maximal cutaneous
309 vasodilation protocol. For the whole-body passive heating protocol, CVC and sweat rate
310 were analyzed with a repeated-measures ANOVA with the factors of stage (two levels:
311 0.6°C and 0.8°C increase in esophageal temperature) and of treatment site (four levels).
312 For the exercise-heat stress test, *post hoc* multiple comparisons were carried out using
313 two-tailed Student's paired t-tests. Based on the previous observations of attenuated
314 and augmented CVC with L-NAME and Nor-NOHA + BEC, respectively (19, 20),
315 responses between treatment sites were compared using one-tailed t-tests in the
316 passive heating protocol. CVC_{max} was evaluated with a one-way repeated measures
317 ANOVA (factor of treatment site). The Holm-Bonferroni correction was employed to
318 account for multiple comparisons. Differences in participant physical characteristics,
319 urine specific gravity and the percent change in body mass between age-groups in the
320 exercise-heat stress protocol were assessed with Student's independent sample t-tests
321 (two-tailed). $P \leq 0.05$ was the level of significance. Unless otherwise mentioned, values
322 were reported as mean \pm 95 % confidence interval (standard error of the mean \times 1.96).
323

324 **RESULTS**325 **Exercise-heat stress**326 *Participant physical characteristics*

327 Table 1 contains the mean \pm standard deviation characteristics of the young and
328 older participants. By design, age was greater in the older vs young men ($P<0.01$). No
329 differences were noted for body height ($P=0.69$), mass ($P=0.30$) or surface area
330 ($P=0.40$) but VO_{2peak} was lower ($P<0.01$) and body fat % was greater ($P<0.01$) in the
331 older men in comparison to their younger counterparts.

332

333 *Body fluid status*

334 No differences in pre-session urine specific gravity were noted between the
335 young (1.013 ± 0.005) and older (1.016 ± 0.006 ; $P=0.41$) men. Further, the change in
336 body mass over the experimental protocol was similar between age-groups (young: -
337 $1.64 \pm 0.28\%$ vs older: $-1.50 \pm 0.28\%$; $P=0.49$).

338

339 *Cutaneous vascular conductance*

340 In the young men, local forearm CVC (main effect of time, $P<0.01$) was elevated
341 during both exercise bouts at all treatment sites (all $P\leq 0.04$) except at L-NAME ($P=0.08$)
342 during the first exercise bout. In contrast, CVC was similar to baseline values at each
343 skin site during both recoveries (all $P\geq 0.10$) with the exception of an elevation at the
344 Nor-NOHA + BEC site during the first recovery ($P<0.01$). Throughout the experimental
345 protocol, CVC (main effect of treatment site, $P<0.01$; figure 1) was reduced relative to

346 Control at L-NAME (all $P < 0.01$) but similar to Control at Nor-NOHA + BEC (all $P \geq 0.43$)
347 and low-dose SNP (all $P \geq 0.18$) in the young men.

348 In the older men, local forearm CVC (main effect of time, $P < 0.01$) was elevated
349 from baseline at Control (both $P < 0.01$), Nor-NOHA + BEC (both $P \leq 0.01$) and low-dose
350 SNP (both $P \leq 0.02$) during both exercise bouts. At L-NAME however, CVC was similar
351 to baseline throughout the experimental protocol (all $P \geq 0.12$). In comparison to Control,
352 CVC (main effect of treatment site, $P < 0.01$; figure 1) was reduced at L-NAME during
353 baseline ($P < 0.01$) and the first ($P = 0.02$) but not second ($P = 0.16$) exercise bout. Further,
354 CVC at L-NAME was attenuated relative to Control in both recoveries (both $P < 0.01$). In
355 contrast, no differences in CVC between Control and both Nor-NOHA + BEC (all
356 $P \geq 0.06$) and low-dose SNP (all $P \geq 0.10$) were noted during the experimental protocol.
357 When a comparison between age groups was made, no differences in CVC at Control
358 were observed during the intermittent exercise protocol (main effect of age, $P = 0.71$).
359 CVC_{max} was similar between and within the young and older adults at all treatment sites
360 (main effects of age and treatment site, both $P \geq 0.71$; table 2).

361

362 *Sweat rate*

363 Local forearm sweat rate (interaction of time and condition, $P = 0.03$; figure 2) was
364 elevated relative to baseline values throughout the intermittent exercise protocol in the
365 young men at all treatment sites. While no between-site differences were observed at
366 baseline (all $P \geq 0.18$) sweat rate was attenuated relative to Control at the L-NAME (both
367 $P \leq 0.03$) but not Nor-NOHA + BEC (both $P \geq 0.57$) or low-dose SNP (both $P \geq 0.38$) skin
368 sites during both exercise bouts. In parallel to baseline, local sweat rate was not

369 different between treatment sites in the young men during both recovery periods (all
370 $P \geq 0.09$). In the older men, local sweat rate (main effect of time, $P < 0.01$) was elevated
371 from baseline at all treatment sites during both exercise bouts and recovery periods (all
372 $P \leq 0.01$); however, sweating responses were similar between treatment sites (main
373 effect of treatment site, $P = 0.28$). Finally, no differences in local sweat rate at Control
374 were noted between age-groups (main effect of age, $P = 0.76$; figure 2).

375

376 *Body temperature and cardiovascular responses*

377 Esophageal temperature (main effect of time, $P < 0.01$; table 3) was elevated from
378 baseline values in the young men during both exercise bouts (both $P < 0.01$) as well as
379 the first ($P < 0.01$) but not second recovery ($P = 0.08$). When expressed as both absolute
380 values and elevations from baseline, esophageal temperature was greater in the
381 second compared to first exercise bout in both age-groups (both $P = 0.02$). In the older
382 adults, esophageal temperature (absolute and relative responses) was elevated from
383 baseline values during both exercise bouts (both $P < 0.01$) and recovery periods (both
384 $P < 0.01$) and was greater in the second exercise relative to the first (both $P = 0.01$).
385 Esophageal temperature was not different between age-groups when expressed in
386 absolute values (main effect of age, $P = 0.61$) but elevations from baseline were greater
387 in the older vs. younger men during both exercise bouts (both $P = 0.01$).

388 Compared to baseline, mean skin temperature (main effect of time, $P < 0.01$; table
389 3) was elevated during both exercise bouts (both $P \leq 0.03$) in the young men. In the older
390 men, mean skin temperature was increased from baseline values throughout both
391 exercise bouts ($P < 0.01$) and during the second recovery period ($P = 0.03$). No

392 differences in mean skin temperature were observed between age-groups whether
393 expressed in absolute values or as a change from baseline (main effect of age, $P=0.61$).

394 Throughout the experimental protocol, mean arterial pressure (interaction of time
395 and age, $P=0.03$; table 4) remained similar to baseline in the young men (all $P>0.01$). In
396 the older men however, mean arterial pressure was elevated from baseline during both
397 exercise bouts (both $P\leq 0.02$) but was attenuated during the second recovery ($P=0.02$).
398 During the first exercise, mean arterial pressure was greater in the older relative to
399 younger men ($P=0.03$). Heart rate (main effect of time, $P<0.01$, table 4) was elevated
400 from baseline during both exercise bouts (both $P<0.01$) in the young and throughout the
401 experimental protocol in the older men (all $P\leq 0.01$). Moreover, in the older men, heart
402 rate increased from the first to second exercise bout ($P<0.01$) and recovery ($P<0.01$).
403 Heart rate was not different between age-groups (main effect of age, $P=0.95$).

404

405 **Whole-body passive heating**

406 The mean \pm standard deviation characteristics of the older men who participated
407 in the whole-body passive heating protocol were: age, 64 ± 7 years; height, 1.75 ± 0.09
408 m; body mass, 77.8 ± 10.4 kg, surface area, 1.93 ± 0.13 m² and body fat, $22.3 \pm 8.1\%$.
409 Participants were adequately hydrated (urine specific gravity <1.020 (3)) prior to the
410 heating protocol (urine specific gravity: 1.012 ± 0.009).

411 At all treatment sites, CVC (temperature-treatment interaction, $P=0.03$) was
412 elevated when esophageal temperature was passively increased from 0.6°C to 0.8°C
413 (all $P\leq 0.02$). In comparison to Control, CVC at the L-NAME skin site was similar when
414 esophageal temperature was elevated 0.6°C ($P=0.09$) but reduced at an increase of

415 0.8°C ($P=0.04$). Arginase inhibition via Nor-NOHA + BEC augmented CVC relative to
416 control at both levels of hyperthermia (both $P\leq 0.05$), whereas no influence of low-dose
417 SNP was noted (both $P\geq 0.33$). CVC_{max} was 2.01 ± 0.50 , 1.79 ± 0.48 , 1.91 ± 0.55 , and
418 1.82 ± 0.55 perfusion units·mm Hg⁻¹ at Control, L-NAME, Nor-NOHA + BEC and Low-
419 dose SNP, respectively, and was similar between treatments (main effect of treatment
420 site, $P=0.89$). Finally, while sweat rate at each skin site increased when the change in
421 esophageal temperature from baseline was elevated from 0.6°C to 0.8°C (all $P\leq 0.01$;
422 main effect of temperature, $P<0.01$), responses were not affected by any treatment
423 (main effect of treatment site, $P=0.83$).

424

425 **DISCUSSION**

426 In the present study the independent influences of age-related increases in
427 arginase activity and changes in NO sensitivity of the thermoregulatory end-organs (i.e.,
428 cutaneous vasculature and the eccrine sweat gland) on cutaneous vasodilation and
429 sweating during exercise in the heat (35°C) were evaluated. We demonstrate that local
430 arginase inhibition (to increase synthesis of endogenous NO via NO synthase) and low-
431 dose SNP administration (to supply exogenous NO) do not independently modulate
432 cutaneous vasodilation or sweating in either young or older men performing moderate-
433 intensity intermittent exercise in the heat (35°C). These results contrast with those
434 observed during whole-body passive heating, wherein arginase inhibition augmented
435 cutaneous vasodilation (but not sweating) at increases in esophageal temperature
436 equivalent to those achieved in the exercise-heat stress test. Altogether our findings
437 provide novel information regarding the control of cutaneous perfusion and sweating

438 during exercise while also highlighting the differential modulation of these responses
439 between exercise- and passively induced heat stress.

440

441 **Arginase**

442 Our hypothesis that age-related changes in the activity of the arginase enzyme
443 (4, 25, 31, 50) influence heat loss responses in older men during exercise was not
444 supported by the current findings. Specifically, increasing local synthesis of endogenous
445 NO via arginase inhibition did not augment the heat loss responses in either age-group,
446 despite reductions in NO-dependent cutaneous vasodilation (figure 1) and sweating
447 (figure 2) in the older men (evidenced by similar responses between the Control and L-
448 NAME skin sites). This contrasts our findings in the whole-body passive heating
449 protocol (figure 3), as well as those of Holowatz *et al.* (19, 20) in which augmented
450 cutaneous vasodilation was observed in older adults when arginase was locally
451 inhibited. While there is currently no explanation for the dissimilar roles for arginase in
452 cutaneous vasodilation between exercise- and passively-induced heat stress, it is
453 known that control of the heat loss responses is influenced by the mode of heating. For
454 example, Fujii *et al* (8) demonstrated that cyclooxygenase contributes to the cutaneous
455 vasodilatory response during exercise in the heat (in an interactive manner with NO)
456 while McCord *et al* (33) did not observe a role for this enzyme in whole-body passive
457 heating.

458 A potential contributor to the discrepancies in the influence of arginase on
459 cutaneous vasodilation may be differences in skin temperature between heating
460 modalities. Exposure to a hot environment (35°C) in the current study resulted in

461 unclamped mean skin temperatures of $\sim 35^{\circ}\text{C}$ whereas the temperature of each
462 treatment site in the study by Holowatz *et al.* (19, 20) was maintained at $\sim 33^{\circ}\text{C}$. *In vitro*,
463 the activity of NO synthase has been shown to be temperature-sensitive and the
464 influence of temperature on the each isoform of the enzyme (i.e., endothelial, neuronal)
465 is inconsistent (48). In the context of the current work, this latter point may be especially
466 important given that endothelial NO synthase is the primary modulator of cutaneous
467 perfusion during exercise (9, 36) whereas the neuronal isoform is implicated during
468 passive heating (36). Additionally, exercise increases cutaneous vessel shear stress,
469 which can augment NO-mediated vasodilation (32), further complicating the comparison
470 of mechanisms between heating modes. Future research should be directed at
471 evaluating the factors associated with exercise (i.e., skin temperature, shear stress) that
472 not only influence NO-dependent heat loss, but also its interaction with the age-related
473 changes in arginase activity.

474

475 **End-organ sensitivity to exogenous NO**

476 Administration of low-dose SNP to provide exogenous NO did not alter
477 cutaneous vasodilation in the young men (figure 1). The relatively consistent
478 contribution of NO to cutaneous vasodilation ($\sim 26\% \text{CVC}_{\text{max}}$ difference between Control
479 and L-NAME) in the young group throughout the experimental protocol suggests that it
480 is exposure to a hot environment and not exercise *per se* that modulates the
481 contribution of NO to cutaneous vasodilation. In other words, NO-dependent cutaneous
482 vasodilation appeared to reach its 'physiological peak' when skin temperature was
483 elevated from thermoneutral values of $\sim 33^{\circ}\text{C}$ to $\sim 35^{\circ}\text{C}$ during the initial resting heat

484 exposure period (~60 min at 35°C ambient temperature) prior to baseline data
485 collection. However, despite an attenuated contribution of NO to cutaneous vasodilation
486 in the second exercise bout, exogenous NO (i.e., low-dose SNP) did not affect
487 cutaneous vasodilation in the older men at any point during exercise heat stress (figure
488 1). Importantly, the lack of an effect of low-dose SNP was also observed during whole-
489 body passive heating (figure 3), suggesting that providing exogenous NO does not
490 modulate cutaneous vasodilation in older adults.

491 Consistent with the findings for cutaneous vasodilation, low-dose SNP did not
492 influence sweat rate in the older men despite a lack of NO-dependent sweating during
493 exercise (figure 2) or whole-body passive heating (figure 3). The age-related alteration
494 in sweating (and potentially cutaneous vasodilation) may therefore stem from
495 modulation of signaling pathways downstream of endogenous NO production. In
496 support of this notion, we have demonstrated that cyclooxygenase contributes to the
497 sweating response in young adults during moderate intensity exercise (heat production
498 of 400 W) in a NO-interactive manner (8). Similarly, recent work suggests that in
499 younger adults, purinergic receptor activation is also an important mediator of sweating
500 during exercise, again via NO-dependent mechanisms (1). However, In parallel to age-
501 related reductions in NO-dependent sweating (1, 11), neither cyclooxygenase (11) nor
502 purinergic receptor (1) blockade modulates exercise-induced sweating in older adults.
503 Combined with the lack of an effect of exogenous NO observed in the present study,
504 those findings suggest that in men, age-related modulation of NO-dependent heat loss
505 is secondary to alterations in pathways downstream of endogenous NO synthesis.

506

507 Considerations

508 Cutaneous vasodilation and sweating at the Control skin site were similar
509 between the young and older men throughout the exercise-heat stress protocol. While
510 age-related impairments in heat exchange are well established (24, 27, 28), they are not
511 always reflected in local measurements (28, 47). Differences in cutaneous vasodilation
512 between young and older adults can be influenced by the site of measurement (44) and
513 a more pronounced separation between groups may have been seen if measurements
514 were performed on the chest or back, skin sites which typically exhibit greater
515 sudomotor activity than the forearm (24). The forearm was chosen to reduce movement
516 artifacts during cycling and to facilitate comparison between previous studies, given that
517 the majority of work aimed at evaluating the mechanisms underpinning these heat loss
518 responses previously employed forearm skin sites (8, 9, 11, 16, 17, 19, 20, 37, 38, 40,
519 45, 46, 49). That said, we observed greater elevations in esophageal temperature
520 during exercise in the older vs. younger men (table 3), despite having both groups
521 exercise at the same absolute heat load (400 W) to elicit similar drives for whole-body
522 heat loss between age-groups (24, 39). Thus, whole-body heat loss was attenuated for
523 a given body core temperature in the older men. Our findings are therefore still
524 indicative of age-related modulation in the control of heat loss during exercise,
525 especially when considering the altered NO-dependent cutaneous vasodilation and
526 sweating (figures 1-3).

527

528 CONCLUSION

529 Our findings suggest that neither elevated arginase activity nor changes in the
530 sensitivity of the thermoregulatory end-organs to exogenous NO affect cutaneous
531 vasodilation and sweating in older men during moderate-intensity intermittent exercise
532 in the heat. By contrast, cutaneous vasodilation was augmented by local arginase
533 inhibition in older men during passive heating. In all, these findings highlight the
534 differential mechanisms underpinning the heat loss responses to both exercise- and
535 passively-induced heat stress. Future work is required to delineate the putative
536 modulators of cutaneous perfusion and sweating with both heating modalities along with
537 their implications for body temperature regulation.

538 **ACKNOWLEDGEMENTS**

539 We thank all volunteers for taking their time to participate in this study and Ms.
540 Pegah Akbari, Ms. Reem Ghassa, Ms. Caroline Muia, Ms. Madison Schmidt and Mr.
541 Jeffery Louie for their roles in data collection.

542

543 **GRANTS**

544 This project was supported by the Canadian Institutes of Health Research
545 (grant# 286363; funds held by Dr. Glen P. Kenny). G. P. Kenny was supported by a
546 University of Ottawa Research Chair Award. R.D. Meade was supported by a Natural
547 Sciences and Engineering Research Council of Canada Alexander Graham Bell
548 graduate scholarships (CGS-D). G.W. McGarr was supported by the Human and
549 Environmental Physiology Research Unit. R.J. Sigal was supported by a Health Senior
550 Scholar award from Alberta Innovates-Health Solutions.

551

552 **DISCLOSURES**

553 None.

554 REFERENCES

- 555 1. **Akbari P, Fujii N, Foudil-bey I, Meade RD, Singh MS, Boulay P, Sigal RJ,**
556 **and Kenny GP.** Sweating During Intermittent Exercise in the Heat in Young and Older
557 Adults: A Role for P2 Receptors. *The FASEB Journal* 30: 1290.1216-1290.1216, 2016.
- 558 2. **al-Tamer YY, and Hadi EA.** Age dependent reference intervals of glucose, urea,
559 protein, lactate and electrolytes in thermally induced sweat. *Eur J Clin Chem Clin*
560 *Biochem* 32: 71-77, 1994.
- 561 3. **American College of Sports Medicine, Sawka MN, Burke LM, Eichner ER,**
562 **Maughan RJ, Montain SJ, and Stachenfeld NS.** American College of Sports Medicine
563 position stand. Exercise and fluid replacement. *Med Sci Sports Exerc* 39: 377-390,
564 2007.
- 565 4. **Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S,**
566 **Shoukas AA, Nyhan D, Champion HC, and Hare JM.** Arginase reciprocally regulates
567 nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood
568 vessels. *Circulation* 108: 2000-2006, 2003.
- 569 5. **Charkoudian N, and Stachenfeld N.** Sex hormone effects on autonomic
570 mechanisms of thermoregulation in humans. *Auton Neurosci* 196: 75-80, 2016.
- 571 6. **Charkoudian N, and Stachenfeld NS.** Reproductive hormone influences on
572 thermoregulation in women. *Compr Physiol* 4: 793-804, 2014.
- 573 7. **Dubois D, and Dubois E.** A formula to estimate the approximate surface area if
574 height and weight be known. *Archives of internal medicine* 17: 863-871, 1916.
- 575 8. **Fujii N, McGinn R, Stapleton JM, Paull G, Meade RD, and Kenny GP.**
576 Evidence for cyclooxygenase-dependent sweating in young males during intermittent
577 exercise in the heat. *J Physiol* 592: 5327-5339, 2014.
- 578 9. **Fujii N, Meade RD, Alexander LM, Akbari P, Foudil-Bey I, Louie JC, Boulay**
579 **P, and Kenny GP.** iNOS-dependent sweating and eNOS-dependent cutaneous
580 vasodilation are evident in younger adults, but are diminished in older adults exercising
581 in the heat. *J Appl Physiol (1985)* 120: 318-327, 2016.
- 582 10. **Fujii N, Meade RD, Minson CT, Brunt VE, Boulay P, Sigal RJ, and Kenny GP.**
583 Cutaneous blood flow during intradermal NO administration in young and older adults:
584 roles for calcium-activated potassium channels and cyclooxygenase? *Am J Physiol*
585 *Regul Integr Comp Physiol* 310: R1081-1087, 2016.
- 586 11. **Fujii N, Paull G, Meade RD, McGinn R, Stapleton JM, Akbari P, and Kenny**
587 **GP.** Do nitric oxide synthase and cyclooxygenase contribute to the heat loss responses
588 in older males exercising in the heat? *J Physiol* 593: 3169-3180, 2015.
- 589 12. **Gagnon D, Jay O, Lemire B, and Kenny GP.** Sex-related differences in
590 evaporative heat loss: the importance of metabolic heat production. *Eur J Appl Physiol*
591 104: 821-829, 2008.
- 592 13. **Gagnon D, and Kenny GP.** Does sex have an independent effect on
593 thermoeffector responses during exercise in the heat? *J Physiol* 590: 5963-5973, 2012.
- 594 14. **Gagnon D, and Kenny GP.** Sex differences in thermoeffector responses during
595 exercise at fixed requirements for heat loss. *J Appl Physiol (1985)* 113: 746-757, 2012.
- 596 15. **Hier SW, Cornbleet T, and Bergeim O.** The amino acids of human sweat. *J Biol*
597 *Chem* 166: 327-333, 1946.

- 598 16. **Hodges GJ, Chiu C, Kosiba WA, Zhao K, and Johnson JM.** The effect of
599 microdialysis needle trauma on cutaneous vascular responses in humans. *J Appl*
600 *Physiol* (1985) 106: 1112-1118, 2009.
- 601 17. **Holowatz LA, Houghton BL, Wong BJ, Wilkins BW, Harding AW, Kenney**
602 **WL, and Minson CT.** Nitric oxide and attenuated reflex cutaneous vasodilation in aged
603 skin. *Am J Physiol Heart Circ Physiol* 284: H1662-1667, 2003.
- 604 18. **Holowatz LA, Thompson-Torgerson C, and Kenney WL.** Aging and the
605 control of human skin blood flow. *Front Biosci (Landmark Ed)* 15: 718-739, 2010.
- 606 19. **Holowatz LA, Thompson CS, and Kenney WL.** Acute ascorbate
607 supplementation alone or combined with arginase inhibition augments reflex cutaneous
608 vasodilation in aged human skin. *Am J Physiol Heart Circ Physiol* 291: H2965-2970,
609 2006.
- 610 20. **Holowatz LA, Thompson CS, and Kenney WL.** L-Arginine supplementation or
611 arginase inhibition augments reflex cutaneous vasodilation in aged human skin. *J*
612 *Physiol* 574: 573-581, 2006.
- 613 21. **Inbar O, Morris N, Epstein Y, and Gass G.** Comparison of thermoregulatory
614 responses to exercise in dry heat among prepubertal boys, young adults and older
615 males. *Exp Physiol* 89: 691-700, 2004.
- 616 22. **Inoue Y, Havenith G, Kenney WL, Loomis JL, and Buskirk ER.** Exercise- and
617 methylcholine-induced sweating responses in older and younger men: effect of heat
618 acclimation and aerobic fitness. *Int J Biometeorol* 42: 210-216, 1999.
- 619 23. **Kenney WL.** Control of heat-induced cutaneous vasodilation in relation to age.
620 *Eur J Appl Physiol Occup Physiol* 57: 120-125, 1988.
- 621 24. **Kenny GP, and Jay O.** Thermometry, calorimetry, and mean body temperature
622 during heat stress. *Compr Physiol* 3: 1689-1719, 2013.
- 623 25. **Kohen R.** Skin antioxidants: their role in aging and in oxidative stress--new
624 approaches for their evaluation. *Biomed Pharmacother* 53: 181-192, 1999.
- 625 26. **Kohl HW, Blair SN, Paffenbarger RS, Macera CA, and Kronenfeld JJ.** A mail
626 survey of physical activity habits as related to measured physical fitness. *American*
627 *Journal of Epidemiology* 127: 1228-1239, 1988.
- 628 27. **Larose J, Boulay P, Sigal RJ, Wright HE, and Kenny GP.** Age-related
629 decrements in heat dissipation during physical activity occur as early as the age of 40.
630 *PLoS One* 8: e83148, 2013.
- 631 28. **Larose J, Boulay P, Wright-Beatty HE, Sigal RJ, Hardcastle S, and Kenny**
632 **GP.** Age-related differences in heat loss capacity occur under both dry and humid heat
633 stress conditions. *J Appl Physiol* (1985) 117: 69-79, 2014.
- 634 29. **Larose J, Wright HE, Sigal RJ, Boulay P, Hardcastle S, and Kenny GP.** Do
635 older females store more heat than younger females during exercise in the heat? *Med*
636 *Sci Sports Exerc* 45: 2265-2276, 2013.
- 637 30. **Larose J, Wright HE, Stapleton J, Sigal RJ, Boulay P, Hardcastle S, and**
638 **Kenny GP.** Whole body heat loss is reduced in older males during short bouts of
639 intermittent exercise. *Am J Physiol Regul Integr Comp Physiol* 305: R619-629, 2013.
- 640 31. **Lu CY, Lee HC, Fahn HJ, and Wei YH.** Oxidative damage elicited by imbalance
641 of free radical scavenging enzymes is associated with large-scale mtDNA deletions in
642 aging human skin. *Mutat Res* 423: 11-21, 1999.

- 643 32. **Maiorana A, O'Driscoll G, Taylor R, and Green D.** Exercise and the nitric oxide
644 vasodilator system. *Sports Med* 33: 1013-1035, 2003.
- 645 33. **McCord GR, Cracowski JL, and Minson CT.** Prostanoids contribute to
646 cutaneous active vasodilation in humans. *Am J Physiol Regul Integr Comp Physiol* 291:
647 R596-602, 2006.
- 648 34. **McGinn R, Fujii N, Swift B, Lamarche DT, and Kenny GP.** Adenosine receptor
649 inhibition attenuates the suppression of postexercise cutaneous blood flow. *J Physiol*
650 592: 2667-2678, 2014.
- 651 35. **McGinn R, Paull G, Meade RD, Fujii N, and Kenny GP.** Mechanisms
652 underlying the postexercise baroreceptor-mediated suppression of heat loss. *Physiol*
653 *Rep* 2: 2014.
- 654 36. **McNamara TC, Keen JT, Simmons GH, Alexander LM, and Wong BJ.**
655 Endothelial nitric oxide synthase mediates the nitric oxide component of reflex
656 cutaneous vasodilatation during dynamic exercise in humans. *J Physiol* 592: 5317-
657 5326, 2014.
- 658 37. **Meade RD, Fujii N, Alexander LM, Paull G, Louie JC, Flouris AD, and Kenny**
659 **GP.** Local infusion of ascorbate augments NO-dependent cutaneous vasodilatation
660 during intense exercise in the heat. *J Physiol* 593: 4055-4065, 2015.
- 661 38. **Meade RD, Fujii N, Poirier MP, Boulay P, Sigal RJ, and Kenny GP.** Oxidative
662 stress does not influence local sweat rate during high-intensity exercise. *Exp Physiol*
663 103: 172-178, 2018.
- 664 39. **Meade RD, and Kenny GP.** Are All Heat Loads Created Equal? *Med Sci Sports*
665 *Exerc* 49: 1796-1804, 2017.
- 666 40. **Meade RD, Louie JC, Poirier MP, McGinn R, Fujii N, and Kenny GP.**
667 Exploring the mechanisms underpinning sweating: the development of a specialized
668 ventilated capsule for use with intradermal microdialysis. *Physiol Rep* 4: 2016.
- 669 41. **Nishi Y.** Measurement of thermal balance in man. In: *Bioengineering, Thermal*
670 *Physiology and Comfort*, edited by Cena K CJ. New York: Elsevier, 1981, p. 29-39.
- 671 42. **Ramanathan NL.** A new weighting system for mean surface temperature of the
672 body. *J Appl Physiol* 19: 531-533, 1964.
- 673 43. **Siri WE.** The gross composition of the body. *Advances in Biological and Medical*
674 *Physics* 4: 239-280, 1956.
- 675 44. **Smith CJ, Alexander LM, and Kenney WL.** Nonuniform, age-related
676 decrements in regional sweating and skin blood flow. *Am J Physiol Regul Integr Comp*
677 *Physiol* 305: R877-885, 2013.
- 678 45. **Stanhewicz AE, Bruning RS, Smith CJ, Kenney WL, and Holowatz LA.** Local
679 tetrahydrobiopterin administration augments reflex cutaneous vasodilation through nitric
680 oxide-dependent mechanisms in aged human skin. *J Appl Physiol (1985)* 112: 791-797,
681 2012.
- 682 46. **Stapleton JM, Fujii N, Carter M, and Kenny GP.** Diminished nitric oxide-
683 dependent sweating in older males during intermittent exercise in the heat. *Exp Physiol*
684 99: 921-932, 2014.
- 685 47. **Stapleton JM, Poirier MP, Flouris AD, Boulay P, Sigal RJ, Malcolm J, and**
686 **Kenny GP.** Aging impairs heat loss, but when does it matter? *J Appl Physiol (1985)*
687 118: 299-309, 2015.

- 688 48. **Venturini G, Colasanti M, Fioravanti E, Bianchini A, and Ascenzi P.** Direct
689 effect of temperature on the catalytic activity of nitric oxide synthases types I, II, and III.
690 *Nitric Oxide* 3: 375-382, 1999.
- 691 49. **Welch G, Foote KM, Hansen C, and Mack GW.** Nonselective NOS inhibition
692 blunts the sweat response to exercise in a warm environment. *J Appl Physiol (1985)*
693 106: 796-803, 2009.
- 694 50. **White AR, Ryoo S, Li D, Champion HC, Steppan J, Wang D, Nyhan D,**
695 **Shoukas AA, Hare JM, and Berkowitz DE.** Knockdown of arginase I restores NO
696 signaling in the vasculature of old rats. *Hypertension* 47: 245-251, 2006.
697
698

699 **FIGURE LEGENDS**

700

701 **Figure 1.** Local forearm cutaneous vascular conductance (CVC; %CVC_{max}) during the
702 two successive exercise bouts performed at a fixed rate of endogenous heat production
703 (400 W) for the young (n=9; top panel) and older (n=9; bottom panel) men. Throughout
704 the exercise-heat stress protocol, four skin sites were continuously perfused via
705 intradermal microdialysis with 1) lactated Ringer's to act as a control; 2) 10 mM N^G-
706 nitro-L-arginine methyl ester (L-NAME,) to inhibit nitric oxide synthase activity; 3) 5 mM
707 N^ω-hydroxy-nor-Arginine + 5 mM S-(2-boronoethyl)-L-cysteine (Nor-NOHA + BEC,), to
708 inhibit arginase activity; or 4) 1 μM sodium nitroprusside (low-dose SNP,), a nitric oxide
709 donor. Values are mean ± 95% confidence interval. Each data point is an average of the
710 last 5 min of each time period. *, P≤0.05 vs. Control.


711

712 **Figure 2.** Local forearm sweat rate (mg·min⁻¹·cm⁻²) during the two successive exercise
713 bouts performed at a fixed rate of endogenous heat production (400 W) for the young
714 (n=9; top panel) and older (n=9; bottom panel) men. Throughout exercise-heat stress
715 protocol, four skin sites were continuously perfused via intradermal microdialysis with 1)
716 lactated Ringer's to act as a control; 2) 10 mM N^G-nitro-L-arginine methyl ester (L-
717 NAME) to inhibit nitric oxide synthase activity; 3) 5 mM N^ω-hydroxy-nor-Arginine + 5 mM
718 S-(2-boronoethyl)-L-cysteine (Nor-NOHA + BEC) to inhibit arginase activity; or 4) 1 μM
719 sodium nitroprusside (low-dose SNP), a nitric oxide donor. Values are mean ± 95%
720 confidence interval. Each data point is an average of the last 5 min of each time period.


721

722 **Figure 3.** Local forearm cutaneous vascular conductance (CVC; %CVC_{max}) and sweat
723 rate (mg·min⁻¹·cm⁻²) during whole-body passive heating to elevations in esophageal
724 temperature (ΔT_{es}) from baseline of 0.6 and 0.8 in a group of older men (n=7).
725 Throughout the passive heating protocol, four skin sites were continuously perfused via
726 intradermal microdialysis with 1) lactated Ringer's to act as a Control; 2) 10 mM NG-
727 nitro-L-arginine methyl ester (L-NAME) to inhibit nitric oxide synthase activity; 3) 5 mM
728 N^ω-hydroxy-nor-Arginine + 5 mM S-(2-boronoethyl)-L-cysteine (Nor-NOHA + BEC) to
729 inhibit arginase activity; or 4) 1 μM sodium nitroprusside (low-dose SNP), a nitric oxide
730 donor. Values are mean ± 95% confidence interval. *, P≤0.05 vs. Control.


731



732
733 **FIGURE 1**
734



735
736 **FIGURE 2**
737



738
739 **FIGURE 3**